- PR Newswire•13 days agoOncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the publication ...
- PR Newswire•2 months ago
SAN DIEGO, June 28, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, presented recent advancements in electroporation (gene electro-transfer) for immunotherapy in two poster presentations at the American Association for Cancer Research (AACR) Special Conference on Engineering and Physical Sciences in Oncology in Boston. New data related to OncoSec's Tissue-based Real-time Adaptive Controlled Electroporation (TRACE™) technology and helical integrated applicator (Helix™) showed that these technologies have the potential to reduce procedural frequency as well as enhance usability by physicians. Together, these novel technologies may improve a patient's experience to gene electro-transfer and improve therapeutic outcomes, which will help broaden the adoption of gene-electro transfer technologies in immunotherapy.
OncoSec Medical Incorporated (ONCS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||1.70 x 500|
|Ask||2.25 x 1000|
|Day's Range||1.68 - 1.74|
|52wk Range||1.36 - 6.94|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.97|
|Avg Vol (3m)||141,595|
|Dividend & Yield||N/A (N/A)|